Lucid Motor said it expects to be cash flow positive late this decade. The company held its first investor day in nearly five years as a public company. The EV company is aiming to hit that target ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

AI-powered dictation startup Wispr Flow has launched its Android app today. The company released its app for Mac and Windows first, then launched on iOS in June 2025. On iOS, users could use Wispr ...

"It’s been a privilege to have a front row seat to the team’s rapid growth and success and see them become the latest Turkish startup to reach unicorn-level status," says previous investor Arcadia. By ...

As an Amazon Associate, we earn from qualifying purchases. TweakTown may also earn commissions from Newegg and other affiliate partners at no extra cost to you. The NZXT H2 Flow is perfect for an SFF ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...